canceldeath
Registry update — unassessed

Vaccination Efficacy With Metformin in Older Adults: A Pilot Study

Trial registry update: COMPLETED. No results reported in the supplied registry record.

RCTMinor significance
Reporter brief

What this changes

The finding has not established an approved change to our evidence assessment.

Source date: Jul 23, 2020 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill

What it does not prove

  • The abstract provided contains no reported findings, so it is impossible to assess what the study does or does not prove about metformin's effect on vaccine response
  • Sample size is not reported, limiting ability to interpret statistical power and generalisability
  • Effect sizes are not reported, preventing assessment of the magnitude of any differences between groups

Extracted from supplied source material; model confidence is not a measured probability of correctness.

Design
Rct
Sample size
—
Duration
22 months
Population
Older adults (men and women)
Primary outcome
Immune responses to flu vaccine
Effect size
—
Significance
Not reported
Journal
UConn Health
Published
Jul 23, 2020

Recorded source passages

Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.

With aging the immune system gets weaker. This makes older adults more susceptible to influenza (flu).
This research is being done to determine if Metformin, an FDA-approved diabetes medication, is effective at enhancing immune responses to flu vaccine in older men and women.
Participants will be randomly assigned to either metformin or placebo treatment for a total of 22 weeks.
Participants will be vaccinated with high-dose flu vaccine after 12 weeks of treatment.
Immune responses will be evaluated throughout the study at 6 time points.

Source versions

Version 1: Superseded

Version 1: Unassessed

Assessment history

One thread per scientific event, no matter how many outlets covered it.

Sign in to join the discussion.

No comments yet

Be the first to weigh in on this evidence.